Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2017
April 2017, Vol 8, No 2
April 2017, Vol 8, No 2
Urelumab Safe and Active as Monotherapy and in Combination with Nivolumab in Several Types of Cancer
By
Walter Alexander
Immunotherapy
,
Personalized Medicine
April 2017, Vol 8, No 2
National Harbor, MD—The investigational CD137 agonist urelumab, given as monotherapy and in combination with the anti–PD-1 monoclonal antibody nivolumab, demonstrated safety and, in some patients with hematologic and solid tumor malignancies, promising antitumor activity, according to results of 2 early-phase studies presented at the 2016 Society for Immunotherapy of Cancer annual meeting.
Read Article
Carfilzomib Maintenance Improves Response in Relapsed Multiple Myeloma After Transplant
By
Wayne Kuznar
Multiple Myeloma
,
Hematologic Malignancies
April 2017, Vol 8, No 2
Orlando, FL—A conditioning regimen before autologous hematopoietic stem-cell transplant (HSCT) consisting of carfilzomib (Kyprolis) plus high-dose melphalan can help sustain posttransplant remission in patients with relapsed multiple myeloma who respond to transplant.
Read Article
Concurrent EGFR and BRAF Inhibition Prolongs PFS in BRAF V600 Mutation–Positive Colorectal Cancer
By
Wayne Kuznar
GI Cancers Symposium
April 2017, Vol 8, No 2
San Francisco, CA—Adding vemurafenib (Zelboraf) to cetuximab (Erbitux) and irinotecan (Camptosar) prolonged progression-free survival (PFS) and improved the disease control rate in patients with
BRAF
V600E mutation–positive colorectal cancer (CRC).
Read Article
Cisplatin Added to Standard Regimen Leads to Unprecedented Response Rate in Patients with Stage IV Pancreatic Cancer
By
Wayne Kuznar
GI Cancers Symposium
April 2017, Vol 8, No 2
San Francisco, CA—The addition of cisplatin to standard therapy with gemcitabine and nab-paclitaxel was associated with a median overall survival (OS) that “has not been seen in stage IV pancreatic cancer,” according to Gayle Jameson, MSN, ACNP-BC, Nurse Practitioner Investigator of Clinical Trials, HonorHealth Research Institute, Scottsdale, AZ, who reported the results from a phase 1b single-arm pilot study using the triplet at the 2017 Gastrointestinal Cancers Symposium.
Read Article
Reduced-Dose Sorafenib with Uptitration in Hepatocellular Carcinoma Is Cost-Saving Without Compromising Outcome
By
Wayne Kuznar
GI Cancers Symposium
April 2017, Vol 8, No 2
San Francisco, CA—Starting at a low dose of sorafenib (Nexavar) and titrating up to the full dose of 800 mg, rather than starting the full dose, does not adversely affect outcomes, while improving tolerability and reducing costs in the treatment of patients with hepatocellular carcinoma (HCC). This was the conclusion from a review of 4900 veterans diagnosed with HCC who were prescribed sorafenib at Veterans Administration (VA) hospitals.
Read Article
In the Literature - April 2017
In the Literature
April 2017, Vol 8, No 2
Read Article
Comparing the Current Value Frameworks in Oncology
By
Meg Barbor, MPH
Value in Oncology
April 2017, Vol 8, No 2
Chicago, IL—Escalating drug prices have put value frameworks in the spotlight, and the identification of the key questions and the audience addressed in each value framework is vital to understanding the value landscape, said Kasia Shields, PharmD, MBA, BCOP, BCPS, Director, Medical Communications, Xcenda/AmerisourceBergen, at the 2016 Hematology/Oncology Pharmacy Association Oncology Pharmacy Practice Management Program.
Read Article
How Washington Is Shaping a New Healthcare Reform
By
Gail Thompson
Value in Oncology
April 2017, Vol 8, No 2
Former Senator Bill Frist, MD, opened the 2017 Cancer Center Business Summit in Las Vegas, NV, in early February, with a smile and a warning that we are in unfamiliar territory as the new Congress and the new administration move into 2017, territory that may occur only 2 or 3 times in a century. He said that, “For the first time since 1929, the GOP [the Republican Party] controls Congress, the White House, most governorships and state houses, as well as the Supreme Court.”
Read Article
Benefit of Extended Adjuvant Aromatase Inhibition in Breast Cancer Now in Question
By
Phoebe Starr
Breast Cancer
,
Solid Tumors
,
Personalized Medicine
April 2017, Vol 8, No 2
San Antonio, TX—Extended adjuvant endocrine therapy beyond 5 years with an aromatase inhibitor (AI) failed to improve disease-free survival (DFS) in patients with hormone receptor (HR)-positive breast cancer who were enrolled in the 3 large National Surgical Adjuvant Breast and Bowel Project (NSABP) B-52, IDEAL, and DATA studies, which were presented at the 2016 San Antonio Breast Cancer Symposium.
Read Article
Dual Anti-HER2 Therapy Boosts Progression-Free Survival in Advanced Breast Cancer
By
Charles Bankhead
Breast Cancer
,
Solid Tumors
,
Personalized Medicine
April 2017, Vol 8, No 2
San Antonio, TX—Two HER2-targeted drugs improve progression-free survival (PFS) compared with a single drug when combined with an aromatase inhibitor in patients with advanced breast cancer, as reported at the 2016 San Antonio Breast Cancer Symposium.
Read Article
Page 2 of 3
1
2
3
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma